Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH
Torquato P, Giusepponi D, Alisi A, Galarini R, Bartolini D, Piroddi M, Goracci L, Di Veroli A, Cruciani G, Crudele A, Nobili V, Galli F
Scientific reports · 17 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Organización sin fines de lucro
- Associazione Italiana per la Ricerca sul Cancro
- Organización sin fines de lucro
- Fondazione Italiana per la Ricerca sul Cancro
- Subvenciones
- Ministero dell’Istruzione, dell’Università e della Ricerca (CTN01_00230_413096)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2019-02-14 · Sci Rep · vol. 9 · número 1 · pág. 2045
- Editorial
- Nature Portfolio
- Citado
- 60 citas · más que el 97% de estudios similares · 6.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 53 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Diet, Metabolism, and Disease · Fatty Acid Research and Health
- Palabras clave
- Docosahexaenoic acid, Multivitamin, Lipidomics, Internal medicine, Arachidonic acid, Medicine, Gastroenterology, Polyunsaturated fatty acid, Docosapentaenoic acid, Randomized controlled trial, Placebo, Vitamin E, Fortified Food, Choline, Fatty acid, Vitamin, Endocrinology, Biochemistry, Biology, Pathology
- MeSH
- liver, humans, choline, vitamin e, fatty acids, omega-3, alpha-linolenic acid, docosahexaenoic acids, eicosapentaenoic acid, arachidonic acid, vitamins, vitamin d, adolescent, child, female, male, lipid metabolism, non-alcoholic fatty liver disease, biomarkers, lipidomics
12 autores
- Pierangelo Torquato🇮🇹University of Perugia
- Danilo Giusepponi🇮🇹Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche
- Anna Alisi🇮🇹Bambino Gesù Children's Hospital
- Roberta Galarini🇮🇹Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche
- Desirée Bartolini🇮🇹University of Perugia
- Marta Piroddi🇮🇹University of Perugia
- Laura Goracci🇮🇹University of Perugia
- Alessandra Di Veroli🇮🇹University of Perugia
- Gabriele Cruciani🇮🇹University of Perugia
- Annalisa Crudele🇮🇹Bambino Gesù Children's Hospital
- Valério Nobili🇮🇹Bambino Gesù Children's Hospital; Sapienza University of Rome
- Francesco Galli🇮🇹 · autor de correspondenciaUniversity of Perugia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Two recent randomized controlled trials demonstrated improved radiographic, histological and hepatometabolic cues of non-alcoholic steatohepatitis (NASH) in pediatric patients treated with the ω-3 fatty acid docosahexaenoic acid (DHA) in combination with vitamin D (VD) or with choline (CHO) and vitamin E (VE), the DHA-VD and DHA-CHO-VE trials, respectively). In the present study we verified the nutritional compliance to these DHA-based multivitamin treatments; lipidomics biomarkers of the reported outcome on NASH indicators were also investigated. Samples were obtained from 30 biopsy-proven pediatric NASH patients of the DHA-CHO-VE trial randomized in multivitamin treatment group and placebo group (n = 15 each), and from 12 patients of the treatment group of the DHA-VD trial. All patients underwent 6-month therapy plus 6 months of follow-up. Plasma samples and clinical data were obtained at baseline and at the end of the study (12 months). Selected biomarkers included the free form of DHA and other ω-3 fatty acid arachidonic acid (AA), indices of the vitamin E status, and some hepatic metabolites of these lipids. Radiographic and histological improvements of treated patients were associated with increased concentrations of DHA, α-linolenic acid and α-tocopherol (i.e. VE), and with decreased AA that was also investigated in complex lipids by untargetd lipidomics. As a result a significantly lowered AA/DHA ratio was observed to represent the main indicator of the response to the DHA-based therapy. Furthermore, baseline levels of AA/DHA showed strong association with NAS and US improvement. A stable correction of DHA AA metabolism interaction is associated with the curative effect of this therapy and may represent a key nutritional endpoint in the clinical management of pediatric NASH.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.